EVALUATION OF NEW ADRENOLYTIC DRUG (REGITINE®) AS TEST FOR PHEOCHROMOCYTOMA
- 30 August 1952
- journal article
- research article
- Published by American Medical Association (AMA) in JAMA
- Vol. 149 (18) , 1628-1634
- https://doi.org/10.1001/jama.1952.02930350016005
Abstract
The diagnosis of hypertension due to increased amounts of circulating epinephrine, arterenol, or both, released by pheochromocytoma is receiving more and more emphasis for two reasons. 1. It has only recently been recognized that many of these tumors cause sustained elevation of blood pressure, which is clinically indistinguishable from essential hypertension, and not paroxysmal attacks of hypertension. 2. Although pheochromocytomas are a comparatively uncommon cause of hypertension, if a correct diagnosis can be made and surgical removal of the tumor accomplished, the persistent elevation of the blood pressure can be decreased. The differential diagnosis, therefore, between essential hypertension, for which there is only palliative treatment, and that caused by a pheochromocytoma, for which there is surgical relief, is an important one. Although clinical experience and diagnostic acumen may suggest strongly the presence of pheochromocytomas, the introduction of various pharmacologic agents as aids in diagnosis has greatly enhanced the accuracy ofKeywords
This publication has 5 references indexed in Scilit:
- USE OF PIPEROXAN AND REGITINE® AS ROUTINE TESTS IN PATIENTS WITH HYPERTENSIONJAMA, 1951
- THE EFFECTS OF DIBENAMINE ON SEVERE HYPERTENSIONAnnals of Internal Medicine, 1950
- THE EFFECT OF C-7337 ON THE CARDIOVASCULAR SYSTEM OF DOGS1950
- TREATMENT OF A PATIENT WITH A PHEOCHROMOCYTOMAJAMA, 1949
- BENZODIOXAN TESTJAMA, 1949